Intra-cellular Therapies, Inc.

This early-stage study tested a long-acting injectable version of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. The goal was to see how the body processes the drug and whether it is safe. Participants received a single shot, and researc…

This study looked at whether adding the drug lumateperone to standard antidepressants is safe for people with major depressive disorder. Over 800 adults took the combination for 26 weeks, and researchers tracked side effects and mood changes. The goal was to see if this add-on th…

This study tested a new drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. The goal was to see if the drug could reduce symptoms like hallucinations and delusions better than a placebo over 6 weeks. The trial compared ITI-007 to b…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia in people experiencing a sudden worsening of their condition. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control. The main goal was to me…

This study looked at how safe and how well the body handles a drug called lumateperone in teenagers aged 13 to 17 with schizophrenia or schizoaffective disorder. 26 teens took the drug by mouth, and researchers measured its levels in the blood and checked for side effects. The go…

This study tested whether a new drug called ITI-007 can reduce schizophrenia symptoms better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took either the drug or a placebo for 28 days. The main goal was to see if their symptom…

This study tested a new medication called ITI-007 (lumateperone) to see if it can safely ease depression in people with bipolar I or II disorder. About 550 adults took either the drug or a placebo for six weeks. Researchers measured mood changes using a standard depression scale.…

This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults aged 18-45. Researchers used PET brain scans to see how much of the drug attached to a specific brain receptor (5-HT2A) and checked safety and drug levels in the blood. The goal was …

This early-stage study tested the safety of a new drug called ITI-333 in 32 healthy adults aged 18 to 45. Participants received either the drug or a placebo once daily for 14 days. The goal was to see how the body processes the drug and check for any side effects. This research h…